1.03

1.90% -0.02

After Hours: 1.03

Cognition Therapeutics Inc (CGTX)

Overview News Price History Financials Discussions Forecast

Cognition Therapeutics Inc stock is traded at $1.03, with a volume of 377.35K. It is down -1.90% in the last 24 hours and up +4.45% over the past month. Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Previous Close:

$1.05

Open:

$1.05

24h Volume:

377.35K

Relative Volume:

0.32

Market Cap:

$97.95M

Revenue:

Net Income/Loss:

$-19.58M

P/E Ratio:

-3.9969

EPS:

-0.2577

Net Cash Flow:

$-20.25M

1W Performance:

+0.98%

1M Performance:

+4.45%

6M Performance:

-2.83%

1Y Performance:

-60.23%

1-Day Range:

$1.01

$1.05

1-Week Range:

$0.9815

$1.07

52-Week Range:

$0.5501

$2.67

Cognition Therapeutics Inc Stock (CGTX) Company Profile

Name

Cognition Therapeutics Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

412-481-2210

Address

2500 WESTCHESTER AVE, PURCHASE

Employee

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

CGTX's Discussions on Twitter

Compare CGTX vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CGTX Cognition Therapeutics Inc	1.03	90.98M	0	-19.58M	-20.25M	-0.2577
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Cognition Therapeutics Inc Stock (CGTX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Upgrade	B. Riley Securities	Neutral → Buy
Jul-30-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Nov-03-21	Initiated	B. Riley Securities	Buy
Nov-03-21	Initiated	Oppenheimer	Outperform

Cognition Therapeutics Inc Stock (CGTX) Latest News

Aug 19, 2026

Cognition (CGTX) Earnings Report: Reported EPS Tops Expectations; Market Reaction: Shares Move 0.22% Lower in the Latest ReadingPreliminary Results - vinanet.vn

Aug 19, 2026

Aug 17, 2026

HC Wainwright Has Bullish Estimate for CGTX Q3 Earnings - MarketBeat

Aug 17, 2026

Aug 16, 2026

Cognition Therapeutics (CGTX) Slips 2.9% to $1.01, Nears Support at $0.96Dealer Delta - vinanet.vn

Aug 16, 2026

Aug 15, 2026

Cognition Therapeutics (NASDAQ:CGTX) Stock Rating Lowered by Wall Street Zen - MarketBeat

Aug 15, 2026

Aug 12, 2026

CGTX FY2026 EPS Forecast Raised by Brookline Capital Markets - MarketBeat

Aug 12, 2026

Aug 09, 2026